These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36632151)

  • 61. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Ciarallo A; Mena E; Blackford A; Nadal R; Antonarakis ES; Eisenberger MA; Carducci MA; Ross AE; Kantoff PW; Holt DP; Dannals RF; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2016 Jan; 57(1):46-53. PubMed ID: 26493203
    [TBL] [Abstract][Full Text] [Related]  

  • 62. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; der Kwast THV; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; der Poel HGV; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Mottet N
    Eur Urol; 2021 Feb; 79(2):263-282. PubMed ID: 33039206
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Iguchi T; Kimura G; Fukasawa S; Suzuki H; Uemura H; Nishimura K; Matsumoto H; Yokomizo A; Armstrong AJ; Rosbrook B; Sugg J; Baron B; Chen L; Kunieda F; Stenzl A
    Int J Urol; 2021 Jul; 28(7):765-773. PubMed ID: 33955599
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.
    Chen J; Qi L; Tang Y; Tang G; Gan Y; Cai Y
    Front Cell Dev Biol; 2022; 10():958180. PubMed ID: 36036001
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.
    Hotte SJ; Finelli A; Chi KN; Canil C; Fleshner N; Kapoor A; Kolinsky M; Malone S; Morash C; Niazi T; Noonan KL; Ong M; Pouliot F; Shayegan B; So AI; Sorabji D; Hew H; Park-Wyllie L; Saad F
    Can Urol Assoc J; 2021 Feb; 15(2):E90-E96. PubMed ID: 32853135
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Response assessment using [
    Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
    Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
    Crawford ED; Bryce AH; Hussain MH; Agarwal N; Beltran H; Cooperberg MR; Petrylak DP; Shore N; Spratt DE; Tagawa ST; Antonarakis ES; Aparicio AM; Armstrong AJ; Boike TP; Calais J; Carducci MA; Chapin BF; Cookson MS; Davis JW; Dorff T; Eggener SE; Feng FY; Gleave M; Higano C; Iagaru A; Morgans AK; Morris M; Murray KS; Poage W; Rettig MB; Sartor O; Scher HI; Sieber P; Small E; Srinivas S; Yu EY; Zhang T; Koo PJ
    JU Open Plus; 2024 Apr; 2(4):. PubMed ID: 38774466
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
    Akaza H; Uemura H; Tsukamoto T; Ozono S; Ogawa O; Sakai H; Oya M; Namiki M; Fukasawa S; Yamaguchi A; Uemura H; Ohashi Y; Maeda H; Saito A; Takeda K; Naito S
    Int J Clin Oncol; 2016 Aug; 21(4):773-782. PubMed ID: 26793974
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
    Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Koi L; Thomas C; Löck S; Krause M; Wirth M; Lohaus F
    Eur Urol Oncol; 2022 Feb; 5(1):44-51. PubMed ID: 34785189
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management.
    Kessel K; Bernemann C; Bögemann M; Rahbar K
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298770
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?
    Heidegger I; Brandt MP; Heck MM
    Urol Oncol; 2020 Apr; 38(4):129-136. PubMed ID: 31953000
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
    Leith A; Kim J; Ribbands A; Clayton E; Yang L; Ghate SR
    Adv Ther; 2022 May; 39(5):2236-2255. PubMed ID: 35316501
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?].
    Vis AN; van Moorselaar RJA
    Ned Tijdschr Geneeskd; 2019 Nov; 163():. PubMed ID: 32073798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.